Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

Exclusion Criteria

• •Cardiogenic shock
• •Target lesion located in left main trunk
• •Bifurcation interventions with a planned 2-stent strategy
• •Vessel size too small for implantation of a 2.5 mm stent by visual estimation
• •Patient requiring staging PCI procedure within 6 months after the index procedure
• •Patients requiring DAPT for more than 2 weeks after the index procedure
• •Contraindications or allergy to cobalt, chromium, platinum, polyzene-F, everolimus, zotarolimus or the inability to take triple therapy for at least 6 months
• •Relevant hematologic deviations: platelet count \<100x10\^9 cells/L or \>600x10\^9 cells/L
• •Active bleeding; bleeding diathesis; recent trauma or major surgery in the last month; history of intracranial bleeding or structural abnormalities; suspected aortic dissection
• •Malignancies or other co-morbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance
• •Pregnancy, present (positive pregnancy test), suspected or planned, breast feeding
• •Known allergy or intolerance to the study medications: ASA, clopidogrel, coumadin and its derivatives
• •Patient's inability to fully cooperate with the study protocol